1142 related articles for article (PubMed ID: 11709730)
1. [Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox].
Buxbaum S; Doerr HW; Allwinn R
Dtsch Med Wochenschr; 2001 Nov; 126(46):1289-93. PubMed ID: 11709730
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
[TBL] [Abstract][Full Text] [Related]
3. Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?
Llenas-García J; Rubio R; Hernando A; Arrazola P; Pulido F
AIDS Care; 2013 Aug; 25(8):980-9. PubMed ID: 23244745
[TBL] [Abstract][Full Text] [Related]
4. Changes in the prevalence of the measles, rubella, varicella-zoster, and mumps virus antibody titers in Japanese pregnant women.
Hanaoka M; Hisano M; Watanabe N; Sugawara K; Kambe Y; Kanda E; Sago H; Kato T; Yamaguchi K
Vaccine; 2013 May; 31(19):2343-7. PubMed ID: 23523405
[TBL] [Abstract][Full Text] [Related]
5. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
6. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
[TBL] [Abstract][Full Text] [Related]
7. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
Shinefield HR; Black S; Kuter BJ
J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
[TBL] [Abstract][Full Text] [Related]
8. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
Dennehy PH; Saracen CL; Peter G
Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
[TBL] [Abstract][Full Text] [Related]
9. [Seroprevalence of antibodies against measles, rubella, mumps and varicella among school children in Madrid].
Gil Miguel A; Astasio Arbiza P; Ortega Molina P; Domínguez Rojas V; González López A
An Esp Pediatr; 1999 May; 50(5):459-62. PubMed ID: 10394183
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
11. [The prevalence of measles, rubella, mumps and chickenpox antibodies in a population of health care workers].
Oliveira J; da Cunha S; Côrte-Real R; Sampaio L; Dais N; Meliço-Silvestre A
Acta Med Port; 1995 Apr; 8(4):206-16. PubMed ID: 7625214
[TBL] [Abstract][Full Text] [Related]
12. [Susceptibility to measles, rubella and parotitis in young adults].
Bayas JM; Vilella A; Vidal J; Nebot X; Carbó JM; Navarro G; Prat A; Asenjo MA; Salleras L
Med Clin (Barc); 1996 Apr; 106(15):561-4. PubMed ID: 8656753
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
14. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
15. The combination measles, mumps, rubella and varicella vaccine in healthy children.
Arbeter AM; Baker L; Starr SE; Plotkin SA
Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
[TBL] [Abstract][Full Text] [Related]
16. [Antibodies against vaccine-preventable diseases in pregnant women and their offspring. Measles, mumps, rubella, poliomyelitis, and varicella].
Sauerbrei A; Prager J; Bischoff A; Wutzler P
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2004 Jan; 47(1):10-5. PubMed ID: 15205818
[TBL] [Abstract][Full Text] [Related]
17. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
D'Angio CT; Boohene PA; Mowrer A; Audet S; Menegus MA; Schmid DS; Beeler JA
Pediatrics; 2007 Mar; 119(3):e574-9. PubMed ID: 17332177
[TBL] [Abstract][Full Text] [Related]
18. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
[TBL] [Abstract][Full Text] [Related]
19. Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer.
Bochennek K; Allwinn R; Langer R; Becker M; Keppler OT; Klingebiel T; Lehrnbecher T
Vaccine; 2014 Jun; 32(27):3357-61. PubMed ID: 24793952
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
